Home Neoplasma 2018 Neoplasma Vol.65, No.5, p.762-768, 2018

Journal info

6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal

Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.65, No.5, p.762-768, 2018

Title: Serum and urinary levels of CD222 in cancer: origin and diagnostic value

Abstract: The mannose 6-phosphate/insulin-like growth factor 2 receptor (CD222, M6P/IGF2R) is a multifunctional transmembrane type I receptor, mostly localized intracellularly and less on the surface of all types of mammalian cells. It is known to both transport lysosomal enzymes through their mannose 6-phosphate moieties and to internalize extracellular ligands such as insulin-like growth factor 2 or plasminogen. CD222 is involved in regulation of cell proliferation, migration, T cell activation and apoptosis, and soluble CD222 has been found in higher concentrations in the sera of liver disease patients. Herein, we analyzed the level of CD222 present in cancer patient serum and urine body fluids and found significantly elevated soluble CD222 levels in cancer patients’ sera compared to healthy controls, irrespective of disease type. The urinary CD222 levels were specifically increased in breast cancer and multiple myeloma. CD222 was present in CD222-positive exosomes in urine, but not in sera, thus identifying different CD222 origins present in human body fluids. These results inspire us to propose serum soluble CD222 as a general biomarker for tumorigenesis.

Keywords: mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R; CD222), cancer, exosomes, biomarker, serum, urine
Published online: 24-Sep-2018
Year: 2018, Volume: 65, Issue: 5 Page From: 762, Page To: 768

download file

© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.